Particolare attenzione è stata dedicate all’estrazione delle informazioni più rilevanti per la pratica clinica quotidiana. I documenti selezionati hanno incluso studi di farmacologia di base, studi clinici, linee guida, revisioni, schede tecniche e bibliografia correlata. Sono state eseguite ricerche su Medline e Cochrane Library usando le keyword ‘trazodone’ AND ‘depression’, per identificare la letteratura più pertinente alla revisione delle proprietà farmacologiche del trazodone e al suo uso nella pratica clinica. Fornire una revisione delle informazioni clinicamente rilevanti relative all’uso del trazodone nel disturbo depressivo maggiore. In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia. Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. An effort was made to give weight to the information that was most relevant for daily clinical practice. European and United States prescribing information was reviewed as well. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Medline and Cochrane Library searches were searched using the keywords ‘trazodone’ AND ‘depression’, to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder. An update on the use of sedative-hypnotic medications in psychiatric disorders. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation. Unintentional trazodone overdoses in children ≤6 years of age: data from poison center over a period of 16 years. Antidepressants and cardiovascular adverse events: A narrative review. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Histamine in the regulation of wakefulness. Rediscovering trazodone for the treatment of major depressive disorder. Trazodone for insomnia: a systematic review.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |